{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:21:02Z","timestamp":1792102862103,"version":"4.4.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jconrel.2025.01.041","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T19:51:32Z","timestamp":1737834692000},"page":"730-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Disclosing long-term tolerance, efficacy and penetration properties of hyaluronic acid-coated latanoprost-loaded liposomes as chronic glaucoma therapy"],"prefix":"10.1016","volume":"379","author":[{"given":"Marco","family":"Brugnera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vicario-de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Ana","family":"Gonz\u00e1lez-Cela-Casamayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe M.","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ferraboschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Andr\u00e9s-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nicoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pescina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Herrero-Vanrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bravo-Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.01.041_bb0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14656566.2012.662219","article-title":"A review of the use of latanoprost for glaucoma since its launch","volume":"13","author":"Digiuni","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/exer.1998.0508","article-title":"Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections","volume":"67","author":"Ocklind","year":"1998","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0015","first-page":"1781","article-title":"Reduced TIGR\/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment","volume":"42","author":"Lindsey","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00002512-200320080-00005","article-title":"Latanoprost : an update of its use in glaucoma and ocular hypertension","volume":"20","author":"Perry","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2415-10-4","article-title":"First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure","volume":"10","author":"Denis","year":"2010","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0030","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/IJG.0000000000001055","article-title":"Intraocular pressure lowering effect of latanoprost as first-line treatment for glaucoma","volume":"27","author":"Aspberg","year":"2018","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109006","article-title":"Topical ocular drug delivery systems: innovations for an unmet need","volume":"218","author":"Yang","year":"2022","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114868","article-title":"Trans-corneal drug delivery strategies in the treatment of ocular diseases","volume":"198","author":"Li","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121105","article-title":"Recent advances in ophthalmic preparations: ocular barriers, dosage forms and routes of administration","volume":"608","author":"Maulvi","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0050","first-page":"1967","article-title":"Latanoprost in the treatment of glaucoma","volume":"8","author":"Alm","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/APO.0000000000000327","article-title":"Understanding the dual dilemma of dry eye and glaucoma: an international review","volume":"9","author":"Nijm","year":"2020","journal-title":"Asia Pac. J. Ophthalmol. (Phila.)"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0065","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/17425247.2021.1872542","article-title":"Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection","volume":"18","author":"L\u00f3pez-Cano","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0070","doi-asserted-by":"crossref","first-page":"13870","DOI":"10.1021\/acs.langmuir.2c02086","article-title":"Maleimide-decorated PEGylated mucoadhesive liposomes for ocular drug delivery","volume":"38","author":"Moiseev","year":"2022","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0075","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/jop.2017.0099","article-title":"Characterization and pharmacokinetics of triamcinolone acetonide-loaded liposomes topical formulations for vitreoretinal drug delivery","volume":"34","author":"Altamirano-Vallejo","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091895","article-title":"Baricitinib liposomes as a new approach for the treatment of Sj\u00f6gren\u2019s syndrome","volume":"14","author":"Garr\u00f3s","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.colsurfb.2015.06.036","article-title":"Liposomal voriconazole (VOR) formulation for improved ocular delivery","volume":"133","author":"de S\u00e1","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000267872","article-title":"Phospholipids in meibomian gland secretion","volume":"28","author":"Greiner","year":"1996","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0100","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3109\/10717544.2014.991952","article-title":"Preparation and ocular pharmacokinetics of hyaluronan acid-modified mucoadhesive liposomes","volume":"23","author":"Lin","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/IJN.S342975","article-title":"Exploring a novel fasudil-phospholipid complex formulated as liposomal thermosensitive in situ gel for glaucoma","volume":"17","author":"Khallaf","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133719","article-title":"Lipid, aqueous and mucin tear film layer stability and permanence within 0.15% liposome crosslinked hyaluronic acid versus 0.15% non-crosslinked hyaluronic acid measured with a novel non-invasive ocular surface analyzer","volume":"11","author":"S\u00e1nchez-Gonz\u00e1lez","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101698","article-title":"Development of lactoferrin-loaded liposomes for the management of dry eye disease and ocular inflammation","volume":"13","author":"L\u00f3pez-Machado","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1039\/D4CS00450G","article-title":"Intrinsic immunomodulatory hydrogels for chronic inflammation","volume":"54","author":"Qian","year":"2025","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpb.2016.11.035","article-title":"Hyaluronan as a promising excipient for ocular drug delivery","volume":"113","author":"Guter","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0130","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/aos.15159","article-title":"Hyaluronic acid in the treatment of dry eye disease","volume":"100","author":"Hynnekleiv","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.8.6.2","article-title":"Physicochemical properties of hyaluronic acid-based lubricant eye drops","volume":"8","author":"Aragona","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0145","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1167\/iovs.13-12081","article-title":"Efficacy of osmoprotectants on prevention and treatment of murine dry eye","volume":"54","author":"Chen","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0150","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/ICO.0b013e318165b19e","article-title":"Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells","volume":"27","author":"Corrales","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.exer.2012.12.001","article-title":"Betaine stabilizes cell volume and protects against apoptosis in human corneal epithelial cells under hyperosmotic stress","volume":"108","author":"Garrett","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2016.04.029","article-title":"Free amino acids: an innovative treatment for ocular surface disease","volume":"787","author":"Rusciano","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.jconrel.2025.01.041_bb0165","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1007\/s13346-024-01584-z","article-title":"Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents","volume":"14","author":"Brugnera","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0170","series-title":"Latanoprost: Uses, Interactions, Mechanism of Action, in, DrugBank Online","author":"DrugBank","year":"2023"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106315","article-title":"Trends in development and quality assessment of pharmaceutical formulations - F2\u03b1 analogues in the glaucoma treatment","volume":"180","author":"Asendrych-Wicik","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0180","series-title":"Metabolite Latanoprost acid: Uses, Interactions, Mechanism of Action, in, DrugBank Online","author":"DrugBank","year":"2023"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0185","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1167\/iovs.14-14700","article-title":"Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film","volume":"55","author":"Vicario De La Torre","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0190","first-page":"1","article-title":"A novel osmoprotective liposomal formulation from synthetic phospholipids to reduce in vitro hyperosmolar stress in dry eye treatments","author":"Casamayor","year":"2022","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0195","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3390\/polym11060929","article-title":"Osmoprotectants in hybrid liposome\/HPMC systems as potential glaucoma treatment","volume":"11","author":"G\u00f3mez-Ballesteros","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108723","article-title":"Combined hyperosmolarity and inflammatory conditions in stressed human corneal epithelial cells and macrophages to evaluate osmoprotective agents as potential DED treatments","volume":"211","author":"L\u00f3pez-Cano","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090476","article-title":"Ex vivo conjunctival retention and transconjunctival transport of poorly soluble drugs using polymeric micelles","volume":"11","author":"Pescina","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1556\/AChrom.26.2014.2.1","article-title":"Simple, fast, and sensitive isocratic high performance liquid chromatography method for the quantification of latanoprost","volume":"26","author":"Mansoor","year":"2014","journal-title":"Acta Chromatogr."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108313","article-title":"Preparation and in vitro\/in vivo evaluations of novel ocular micelle formulations of hesperetin with glycyrrhizin as a nanocarrier","volume":"202","author":"Zhang","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121948","article-title":"Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection","volume":"623","author":"L\u00f3pez-Cano","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0225","series-title":"Test No. 491: Short Time Exposure In Vitro Test Method for Identifying (i) Chemicals Inducing Serious Eye Damage and (ii) Chemicals Not Requiring Classification for Eye Irritation or Serious Eye Damage","author":"OECD","year":"2023"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0230","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1167\/iovs.05-0495","article-title":"Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance","volume":"47","author":"Enr\u00edquez de Salamanca","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0235","series-title":"Guideline on non-clinical local tolerance testing of medicinal products (EMA\/CHMP\/SWP\/2145\/2000) Rev 1, Corr 1, in","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0278-6915(93)90121-E","article-title":"The use of low-volume dosing in the eye irritation test","volume":"31","author":"Lambert","year":"1993","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0245","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0039-6257(01)00211-9","article-title":"The Draize eye test","volume":"45","author":"Wilhelmus","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0250","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/erm.12.142","article-title":"TearLab\u00ae Osmolarity System for diagnosing dry eye","volume":"13","author":"Versura","year":"2013","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0260","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/ICO.0b013e3182532047","article-title":"Evaluation of tear osmolarity in non-Sj\u00f6gren and Sj\u00f6gren syndrome dry eye patients with the TearLab system","volume":"31","author":"Szalai","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clae.2010.01.003","article-title":"Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness","volume":"33","author":"Benelli","year":"2010","journal-title":"Cont. Lens Anterior Eye"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0270","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1111\/aos.13887","article-title":"Evaluation of tear meniscus by optical coherence tomography after different sodium hyaluronate eyedrops instillation","volume":"97","author":"Carracedo","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0275","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.eye.6702204","article-title":"Diagnostic performance of tear function tests in Sjogren\u2019s syndrome patients","volume":"21","author":"Versura","year":"2007","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0280","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0285","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/ICO.0000000000002148","article-title":"Efficacy of the fluorescein tear breakup time test in dry eye","volume":"39","author":"Paugh","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0290","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/02713683.2018.1457164","article-title":"Tear film stability and tear break up time (TBUT) in laboratory rabbits-a systematic review","volume":"43","author":"Doughty","year":"2018","journal-title":"Curr. Eye Res."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2025.01.041_bb0295","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0039-6257(02)00296-5","article-title":"The effect of latanoprost on circadian intraocular pressure","volume":"47","author":"Larsson","year":"2002","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0300","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2460\/ajvr.76.7.625","article-title":"Comparison of two- and three-times-daily topical ophthalmic application of 0.005% latanoprost solution in clinically normal dogs","volume":"76","author":"Tofflemire","year":"2015","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0305","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nmeth818","article-title":"Deep tissue two-photon microscopy","volume":"2","author":"Helmchen","year":"2005","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0310","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jconrel.2022.07.019","article-title":"Cyclosporine-loaded micelles for ocular delivery: investigating the penetration mechanisms","volume":"349","author":"Ghezzi","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020407","article-title":"Nanostructured lipid carriers for enhanced transscleral delivery of dexamethasone acetate: development, ex vivo characterization and multiphoton microscopy studies","volume":"15","author":"Gonz\u00e1lez-Fern\u00e1ndez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122911","article-title":"Hyaluronic acid - PVA films for the simultaneous delivery of dexamethasone and levofloxacin to ocular tissues","volume":"638","author":"Ghezzi","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124141","article-title":"A sterilizable platform based on crosslinked xanthan gum for controlled-release of polymeric micelles: ocular application for the delivery of neuroprotective compounds to the posterior eye segment","volume":"657","author":"Signorini","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0330","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1167\/iovs.04-1520","article-title":"Multiphoton autofluorescence and second-harmonic generation imaging of the ex vivo porcine eye","volume":"47","author":"Teng","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0335","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/157340612801216283","article-title":"Prodrug strategies in ocular drug delivery","volume":"8","author":"Barot","year":"2012","journal-title":"Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/pt0801001","article-title":"Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies","volume":"8","author":"Hathout","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0345","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1208\/s12249-015-0382-1","article-title":"Liposomes as a novel ocular delivery system for brinzolamide: in vitro and in vivo studies","volume":"17","author":"Li","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122010","article-title":"Synergistic effect of acetazolamide-(2-hydroxy)propyl \u03b2-cyclodextrin in timolol liposomes for decreasing and prolonging intraocular pressure levels","volume":"13","author":"Arroyo-Garc\u00eda","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0355","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s13346-022-01266-8","article-title":"Cationic liposomes as promising vehicles for timolol\/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro\/in vivo evaluation","volume":"13","author":"Bigdeli","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0360","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/pharmaceutics14071405","article-title":"Novel osmoprotective DOPC-DMPC liposomes loaded with antihypertensive drugs as potential strategy for glaucoma treatment","volume":"14","author":"Gonz\u00e1lez-Cela-Casamayor","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0365","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jfo.2015.09.011","article-title":"Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient","volume":"39","author":"Viaud-Quentric","year":"2016","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0370","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2017.10.007","article-title":"Hyalugel-integrated liposomes as a novel ocular nanosized delivery system of fluconazole with promising prolonged effect","volume":"534","author":"Moustafa","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0375","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.colsurfb.2016.03.061","article-title":"The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system","volume":"143","author":"Chen","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0380","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-3659(99)00192-3","article-title":"Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption","volume":"63","author":"Law","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.103045","article-title":"How liposomes pave the way for ocular drug delivery after topical administration","volume":"67","author":"Tasharrofi","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0390","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2018.07.034","article-title":"Esterase activity in porcine and albino rabbit ocular tissues","volume":"123","author":"Heikkinen","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0395","first-page":"897","article-title":"Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review","volume":"2","author":"Russo","year":"2008","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0400","first-page":"627","article-title":"Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera","volume":"38","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071479","article-title":"Hyaluronic acid: its versatile use in ocular drug delivery with a specific focus on hyaluronic acid-based polyelectrolyte complexes","volume":"14","author":"Casey-Power","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0410","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/eye.2017.73","article-title":"Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye","volume":"31","author":"Labetoulle","year":"2017","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0415","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/aos.15725","article-title":"How latanoprost changed glaucoma management","volume":"102","author":"Cordeiro","year":"2024","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0420","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s40123-023-00769-y","article-title":"Impact of latanoprost antiglaucoma eyedrops and their excipients on toxicity and healing characteristics in the ex vivo eye irritation test system","volume":"12","author":"Panfil","year":"2023","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.jconrel.2025.01.041_bb0425","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4103\/ijo.IJO_2100_18","article-title":"Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma","volume":"67","author":"Lee","year":"2019","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0430","doi-asserted-by":"crossref","first-page":"823","DOI":"10.18410\/jebmh\/2020\/178","article-title":"Topical prostaglandin analogues with and without preservatives on tear film stability in the long-term treatment of glaucoma","volume":"7","author":"Ashraf","year":"2020","journal-title":"J. Evidenc. Based Med. Healthc."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020544","article-title":"The effect of high molecular weight hyaluronic acid and latanoprost eyedrops on tear functions and ocular surface status in C57\/BL6 mice","volume":"12","author":"Dogru","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2025.01.041_bb0440","article-title":"Development and in vitro\/in vivo evaluation of liposomal gels for the sustained ocular delivery of latanoprost","volume":"6","author":"Fathalla","year":"2015","journal-title":"J. Clin. Exp. Ophthalmol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T16:50:48Z","timestamp":1751215848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":88,"alternative-id":["S0168365925000513"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.041","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disclosing long-term tolerance, efficacy and penetration properties of hyaluronic acid-coated latanoprost-loaded liposomes as chronic glaucoma therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}